Embryyo is a med-tech studio designed to create a pipeline of transformative pure play medical devices, driving them from ideation-to-adoption-to-exit, each with the potential to disrupt standard-of-care in global patient populations.
WHAT Better / faster / cheaper ways to see / reach / treat the human body will continue to make the established gold standards obsolete and redundant.
WHERE New challenges are hidden at the unique interfaces of contemporary understanding of human physiology, advances in physical sciences that can be reduced to practice and designs that are context-appropriate and empathetic to the end-user. HOW We are driven to address such challenges with solutions derived from nuanced insights into the problem, based on transformative ideas and realized with entrepreneurial hustle. WHY The endpoint of all our endeavors is to create multidimensional value which 1) creates quantum shifts in patient care, 2) alleviates cost burdens for the provider and the payer, and 3) generates multifold impact and returns for investors. In a nutshell, here's what we do -
|
DiscoverIdentify and select novel, unmet medical device opportunities in niche, high-momentum, high-growth clinical sub-domains
|
RealizeInvent and de-risk early-stage technologies and product concepts and create asset-rich med-tech portfolio companies
|
TranslateCommercialize by means of out-licensing and M&A of portfolio companies to strategic partners, maximizing value creation
|
We are dauntlessly moving the needle in patient-care, with one medical device at a time!
A quick overview of our asset-classes and ongoing developments and explorations -
Pre-FDA devices / technologies to be commercialized through out-licensing -
|
Post-FDA devices being self-commercialized through an Embryyo spin-off -
|
Seeding ideas for a healthier planet!(TM)